XNASTRAW
Market cap169mUSD
Jan 10, Last price
8.06USD
1D
-0.12%
1Q
54.41%
Jan 2017
-76.33%
IPO
-59.86%
Name
Onconova Therapeutics Inc
Chart & Performance
P/E
—
P/S
749.06
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
122.43%
Rev. gr., 5y
-28.72%
Revenues
226k
0.00%
Net income
-19m
L+3.54%
CFO
-18m
L+10.05%
Earnings
Mar 31, 2025
Profile
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 226 0.00% | 226 0.00% | |||||||
Cost of revenue | (225,979,250) | 19,867 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 225,979,476 | (19,641) | |||||||
NOPBT Margin | 99,990,918.58% | ||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | 225,979,476 | (19,641) | |||||||
Net income | (18,948) 3.54% | (18,301) 15.62% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | (3,374,996,625) | ||||||||
Long-term debt | |||||||||
Deferred revenue | 2,791 | 3,017 | |||||||
Other long-term liabilities | |||||||||
Net debt | (3,375,017,446) | (38,757) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (17,932) | (16,294) | |||||||
CAPEX | (14) | ||||||||
Cash from investing activities | (14) | ||||||||
Cash from financing activities | (17,935,982,064) | ||||||||
FCF | 3,600,962,663 | (19,627) | |||||||
| Balance | |||||||||
Cash | 20,821 | 38,757 | |||||||
Long term investments | |||||||||
Excess cash | 20,810 | 38,746 | |||||||
Stockholders' equity | (482,444) | (463,507) | |||||||
Invested Capital | (3,374,500,718) | 494,833 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 20,989 | 20,908 | |||||||
Price | 0.75 15.47% | 0.65 -74.68% | |||||||
Market cap | 15,649 15.92% | 13,500 -68.55% | |||||||
EV | (3,375,001,797) | (25,257) | |||||||
EBITDA | 225,979,492 | (19,627) | |||||||
EV/EBITDA | 1.29 | ||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||